Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Goat Polyclonal (IgG) to Human CDKN1A / WAF1 / p21
IHC - Paraffin, Western blot, Immunoprecipitation, Flow Cytometry
Human CDKN1A / WAF1 / p21
Human (tested or 100% immunogen sequence identity)
IHC - Paraffin (5 - 15 µg/ml)
Western blot (0.5 µg/ml)
Immunoprecipitation (1 - 2 µg/tst)
Specificity and Use
CDKN1A / WAF1 / p21 antibody was raised against e. coli-derived recombinant human p21 Ser2-Pro164 Accession # P38936.
Detects human p21 in Western blots.
Western Blot, 0.5 µg/ml. Immunohistochemistry, 5-15 µg/ml. Immunoprecipitation, 1-2 ug/500 ug cell, MCF-7 human breast cancer cell line. lysate. Intracellular Staining by Flow Cytometry, 2.5 µg/106 cells.
Lyophilized from 0.2 um filtered solution in PBS, trehalose
Sterile PBS. Resuspend to 500 ul
Long term: -20°C; Short term: +4°C; Avoid freeze-thaw cycles.
CDKN1A / WAF1 / p21 is a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli.
p21/CIP1/CDKN1A in Human Breast Cancer Tissue. p21/CIP1/CDKN1A was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using 1.7 ug/ml Goat Anti-Human p21/CIP1/CDKN1A Antigen Affinity-purified Polyclonal Antibody overnight at 4°C. Tissue was stained with Anti-Goat HRP-DAB (brown) and counterstained with hematoxylin (blue).
Detection of Human p21/CIP1/CDKN1A by Western Blot. Western blot shows lysates of MCF-7 human breast cancer cell line untreated (-) or treated (+) with 1 uM camptothecin (CPT) for 16 hours. PVDF membrane was probed with 0.5 ug/ml of Goat Anti-Human p21/CIP1/CDKN1A Antigen Affinity-purified Polyclonal Antibody, followed by HRP-conjugated Anti-Goat IgG Secondary Antibody. A specific band was detected for p21/CIP1/CDKN1A at approximately 21 kD (as indicated). This experiment was conducted under reducing conditions.
Detection of p21/CIP1/CDKN1A in MCF-7 Human Cell Line by Flow Cytometry. M C F-7 human breast cancer cell line was unstimulated (light orange filled histogram) or treated with 1 uM camptothecin for 16 hours, then stained with Goat Anti-Human p21/CIP1/CDKN1A Antigen Affinity-purified Polyclonal Antibody or isotype control antibody, followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody. To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with methanol.
Requested From: United States
Date Requested: 2/26/2017